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httpicense.Abstract Aim of the work: The aim of the present study was to measure the level of the chemokine
CXC ligand 13 protein (CXCL13) in the plasma and unstimulated saliva of rheumatoid arthritis
(RA) patients in order to ﬁnd out its role in the disease activity and its relation to secondary Sjo¨-
gren’s syndrome (sSS).
Patients and methods: The study was conducted on thirty rheumatoid arthritis patients attending
the Outpatient Clinic of Rheumatology and Rehabilitation department of Ain shams University
Hospitals. The patients’ group had been classiﬁed into group (1) which included ﬁfteen RA patients
associated with sSS diagnosed according to the American–European Consensus Group Classiﬁca-
tion Criteria and group (2) which included ﬁfteen RA patients not associated with sSS. Ten healthy
subjects were included as a control group. Patients were subjected to full history taking, clinical
examination, and laboratory detection of CXCL13 level in the plasma and saliva of patients as well
as the control groups using ELISA technique. Assessment of disease activity in RA patients was
done using the disease activity score (DAS28).
Results: Plasma levels of CXCL13 were signiﬁcantly higher in RA patients than control group
(p< 0.001). Plasma levels of CXCL13 were signiﬁcantly correlated with the RA disease activity
(r= 0.677, p< 0.001) and disease duration (r= 0.406, p< 0.05), while the salivary levels were
higher in those with sSS and correlated with sSS disease duration (r= 0.536, p< 0.05). A highly
signiﬁcant correlation was found between salivary CXCL13 and severity of sSS (r= 0.816,
p< 0.001). Salivary levels of CXCL13 above 110 pg/ml may diagnose sSS with sensitivity 80%
and speciﬁcity 84%.31 Hassan Aﬂaton Street,
.com (S.E. Ibrahim).
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ker for RA disease activity, its role in diagnosing sSS, and estimation of sSS severity.
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Rheumatoid arthritis (RA) is a chronic systemic autoimmune
disease characterized by an inﬂammatory erosive synovitis.
This chronic inﬂammatory condition induces changes in the
cellular composition and in the gene expression proﬁle of the
synovial membrane, resulting in intimal lining ﬁbroblast like
synoviocytes hyperplasia and sublining inﬁltration with mono-
nuclear cells, especially CD4 + T cells, macrophages, and B
cells [1]. The disease is characterized by acute painful inﬂam-
matory episodes, destructive changes of the joints that result
in deformity and progressive functional impairment of joints
[2]. Although RA is properly considered a disease of the joints,
abnormal immune responses can cause a variety of extra-artic-
ular manifestations. In some cases, production of rheumatoid
factor (RF) with the formation of immune complexes that ﬁx
complement contributes to extra-articular ﬁndings [3].
Secondary Sjo¨gren’s syndrome is usually included as an ex-
tra-articular manifestation of rheumatoid arthritis [4] which
occurs in approximately 35% of patients, where the involve-
ment of exocrine lacrimal and salivary glands happens. It
was found that the average time between occurrence of their
ﬁrst symptoms and diagnosis of SS was 7.1 years [5].
Markers such as the erythrocyte sedimentation rate (ESR)
and C-reactive protein (CRP) level have been incorporated
into disease activity assessment in patients with RA [6]. How-
ever, both the ESR and CRP are nonspeciﬁc markers of
inﬂammation and also can be increased by aging, anemia,
and the presence of immunoglobulins, including RF [7]. Fur-
thermore, normal levels of these markers are seen in some
RA patients with active disease [8]. Therefore, these markers
may not be helpful in all RA patients.
The chemokine CXC ligand 13 protein (CXCL13), also
known as B-cell-attracting chemokine-1 or B-lymphocyte che-
moattractant (BLC), is a CXC subtype member of the chemo-
kine superfamily. Chemokines have been shown to orchestrate
migration and preferential sequestration of B and T cells in
inﬂammatory lesions [9].
BLC (CXCL13), a CXC chemokine, is the only chemokine
which is known to speciﬁcally chemoattract B cells, belonging
to both B-1 and B-2 subsets through the interaction with its
receptor CXCR5. The gene for CXCL13 is located on human
chromosome 4 in a cluster of other CXC chemokines. CXCL13
and CXCR5 together control the organization of B cells within
follicles of lymphoid tissues and are expressed highly in the liver,
spleen, lymph nodes, and gut of humans [10]. Plasma levels of
CXCL13 provide an accurate test for deﬁning the disease activ-
ity in RA patients [11]. Moreover, it was found that B cells have
been implicated in the pathogenesis of SS and CXCL13 is a
homeostatic chemokine that regulates B cell movement [12].
Therefore CXCL13 may be pathogenetically involved in the
progression and severity of sSS.
A prior study on mice had approved the speciﬁc role of sal-
ivary CXCL13 in the diagnosis of sSS [13]. The current study
may be the ﬁrst one done on Egyptians using a measurement ofCXCL13 levels in the saliva to determine its role in patients
with sSS, as saliva can be obtained easily, providing a non-
invasive, rapid and economical method.
The aim of this work is to measure the level of CXCL13 in
the plasma and unstimulated saliva of RA patients in order to
ﬁnd out its role in the disease activity and its relation to sec-
ondary Sjo¨gren’s syndrome.
2. Patients and methods
The study was conducted on thirty rheumatoid arthritis
patients attending the Outpatient Clinic of Rheumatology
and Rehabilitation of Ain shams University Hospitals. Diag-
nosis was made according to American college of Rheumatol-
ogy (ACR) and European League Against Rheumatism
(EULAR) new classiﬁcation criteria [14]. Ten healthy subjects
were included as a control group. Informed consents were ta-
ken from each patient and control. The study was approved by
Ain Shams medical ethical committee. The study was done in
the period between June 2011 and April 2012.
The patients were classiﬁed into two equal subgroups as
follows:
Group (1) which included ﬁfteen RA patients associated
with manifestations of sSS diagnosed according to the Ameri-
can–European Consensus Group Classiﬁcation Criteria [15].
Group (2) which included ﬁfteen RA patients not associated
with manifestations of sSS.
Patients with malignant diseases, acute infection [16], on
cyclophosphamide therapy [17], post head and neck radiation
treatment, use of anti cholinergic drugs, facial paralysis, pa-
tients with sSS related to other rheumatological diseases were
excluded from the study.
Patients were subjected to:
1. Full medical history taking,
2. Thorough clinical examination,
3. Routine laboratory investigations as:
 Complete blood count (CBC) using Coulter counter
apparatus.
 Erythrocyte Sedimentation Rate (ESR) with Westergren
method.
 C - reactive protein (CRP) in milligram per deciliter (mg/dl).
 Rheumatoid Factor (RF) with Latex ﬁxation technique.
 Anti- cyclic citrullinated peptide assay (anti-CCP) by
enzyme-linked immunosorbent assay (ELISA) (Euro-Diag-
nostica, the Netherlands).
4. Quantitative detection of CXCL13 level in plasma and
saliva of the patients and control,
5. Using ELISA technique (Quantikine Human CXCL13
immuno-essay R &D systems, Minneapolis, MN: USA).
6. Assessment of disease activity in RA patients: Using the
disease activity score (DAS28) [18]. Mild 63.2, moderate
P3.2 but 65.1, severe >5.1. 6-Assessment of disease
severity in sSS patients: using Lissamine green stain
score [15]:
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the white of the eye between the lids toward the nose. This
so-called nasal staining does not necessarily predict dry eye;
it might be caused by environmental factors, such as
pollution.
 The second level appears as stains in the white of the eye
between the lids but toward the ear (Temporal conjunctiva)
and called temporal staining.
 The third and most severe level occurs when the stain also
appears on the cornea, indicating a break in the surface cells
where bacteria can penetrate.
Statistical analysis: Analysis of data was performed by
IBM computer using statistical package for social science
(SPSS) version 16. Data were expressed as mean, standard
deviation, and range. Number and percentage were used to
describe qualitative variables. The comparison between two
groups with parametric variables was done using indepen-
dent sample t-test (t). ANOVA test was used to assess the
statistical signiﬁcance of the difference between more than
two study group means. The correlation coefﬁcient between
two parametric parameters was calculated by using Pearson
correlation coefﬁcient. Chi-Square test was used to examine
the relationship between two qualitative variables. The ROC
Curve (receiver operating characteristic) provides a useful
way to evaluate the Sensitivity and speciﬁcity for quantita-
tive diagnostic measures that categorize cases into one of
two groups. In all tests if (p> 0.05) it is non signiﬁcant,
if (p< 0.05) it is signiﬁcant and if (p< 0.001) it is highly
signiﬁcant.
3. Results
The study was conducted on thirty RA patients and they were
further classiﬁed according to whether or not they had of sSS
into two equal subgroups (group 1 and group 2) respectively
matching in age and sex, and ten normal subjects serving as
control group.Table 1 Laboratory data of RA patients and control group.
Laboratory data Rheumatoid arthritis (RA) patients
With sSS (n= 15) Wit
Range Mean ± SD Ran
ESR (mm/h) 30–130 82.5 ± 27.3 10
CRP (mg/dl) 3–64 29.1 ± 22.2
WBC count (103/mm3) 2.5–16.6 7.7 ± 4.3 3.3–
Hb concentration (gm/dl) 7.6–13.1 8.7 ± 3.4 7.1–
RBC count (106/mm3) 2.8–4.8 3.5 ± 0.7 2.5
Platelets count (103/mm3) 130–470 260.5 ± 90.5 137
Lymphocytes count(103/mm3) 0.9–2.9 1.7 ± 0.5 0.9
RF positive No. %
Anti-CCP 12 80
13 86.6
RA: rheumatoid arthritis, sSS: secondary Sjogren’s syndrome, No.: num
reactive protein, WBC: white blood cell, Hb: hemoglobin, RBC: red bl
peptide.3.1. The patients’ groups
Group 1: It included 15 RA patients with manifestations of sSS
(50%), they were 14 females (93.3%) and one male (6.7%),
their age ranged from 30 to 62 years with a mean age of
50 ± 10.87. The disease duration of RA ranged from 2.5 to
30 years with a mean of 12.8 ± 9, the disease duration of
sSS ranged from 1 to 6 years with a mean of 2.8 ± 1.6.
Group 2: It included 15 RA patients without manifestations
of sSS (50%), they were 14 females (93.3%) and one male
(6.7%), their age ranged from 17 to 62 years with a mean of
age 43.53 ± 12.98. The disease duration of RA ranged from
0.2 to 14 years with a mean of 6.1 ± 4.9.
3.2. The control group
It included 10 normal subjects, 9 females (90%) and 1 male
(10%), their age ranged from 27 to 60 years with a mean age
of 41.9 ± 11.57.
On comparing the patients’ and control groups, there was
no statistically signiﬁcant difference as regards age and sex dis-
tribution (p> 0.05).
4. Laboratory data
The laboratory data of the patients and controls are shown in
Table 1.
Estimation of the plasma and salivary CXCL13 in all pa-
tients and controls is presented in Table 2.
5. Assessment of RA disease activity
- Group 1: DAS28 showed values ranging from 3.1 to 6.1
with a mean 5.5 ± 0.8. There was only 1 patient
(6.7%) with mild RA disease activity, 8 patients
(53.3%) had moderate RA activity, and 6 patients
(40%) had severe activity of RA, as regards severity ofp Control (n= 10)
hout sSS (n= 15)
ge Mean ± SD Range Mean ± SD
–105 61.9 ± 23.5 0.04 8–11 8.4 ± 3.9
4–64 21.6 ± 19.2 0.33 4–7 6.8 ± 2
16.6 8.1 ± 4.1 0.07 4.1–11 8.1 ± 3.1
14.1 9.2 ± 3.2 0.07 12–15.1 13.7 ± 2.6
–4.8 3.9 ± 0.7 0.64 3.9–4.8 4.3 ± 0.8
–470 270.5 ± 92.5 0.36 235–440 330.5 ± 110.5
–2.9 1.4 ± 0.7 0.45 1.5–3.3 2.1 ± 0.9
No. % 0.07
10 66.7
11 73.3
ber, %: Percentage, ESR: erythrocyte sedimentation rate, CRP: C
ood cell, RF: rheumatoid factor, Anti-CCP: anticyclic citrullinated
Table 2 CXCL13 plasma and salivary levels in the patients with and without sSS and controls.
Variables Rheumatoid arthritis (RA) patients p Control (n= 10)
With sSS (n= 15) Without sSS (n= 15)
Range Mean ± SD Range Mean ± SD Range Mean ± SD
CXCL13 plasma (pg/ml) 30–250 136.7 ± 62.9 60–400 164.7 ± 90.7 0.335 9–15 11.5 ± 2.2
CXCL13 saliva (pg/ml) 85–355 206 ± 99.6 15–160 80 ± 42.1 0.001 8–13 10.6 ± 1.9
RA: rheumatoid arthritis, sSS: secondary Sjo¨gren’s syndrome.
124 N.M. Sherif et al.sSS there were 4 patients (26.7%) with mild sSS, 5
patients (33.3%) had moderate sSS, and 6 patients
(40%) had severe sSS.
- Group 2: DAS28 showed values ranged from 3.4 to 6.5 with
a mean 5.1 ± 0.9. There were 3 patients (20%) with mild
RA activity, 9 patients (60%) had moderate RA activity
and 3 patients (20%) had severe active RA.
6. Comparison between the RA patients with sSS, RA without
sSS and control group as regards plasma and salivary levels of
CXCL13
There was a statistically highly signiﬁcant difference
(p< 0.001) between both patients’ groups and the control
group as regards the mean levels of plasma and salivary
CXCL13.
7. The correlation between the disease duration of RA patients
with sSS, RA without sSS and levels of plasma and salivary
CXCL13
Concerning the RA disease duration, there was a statistically
signiﬁcant positive correlation with plasma CXCL13 levels
(r= 0.406, p< 0.05), while there was no statistically signiﬁ-
cant correlation with salivary CXCL13 (r= 0.049,
p> 0.05). Concerning the disease duration of sSS, there was
a statistically signiﬁcant positive correlation with salivary
CXCL13 levels (r= 0.536, p< 0.05), while there was no sta-
tistically signiﬁcant correlation with plasma CXCL13 levels
(r= 0.085, p> 0.05).
There was no statistically signiﬁcant correlation between
the salivary levels of CXCL13 and each of ESR and CRP
(r= 0.242, 0.21 respectively, p> 0.05), but there was a statis-
tically signiﬁcant positive correlation between plasma level of
CXCL13 and ESR as well as CRP(r= 0.3, p< 0.05).
CXCL13 plasma levels had a statistically highly signiﬁcant
positive correlation with the activity of RA (DAS28 ESR)
(r= 0.677 & p< 0.001and no statistical signiﬁcance with
severity of SS (r= 0.091, p> 0.05). There was no statistically
signiﬁcant correlation between salivary CXCL13 and activity
of RA (r= 0.104, p> 0.05), but a statistically highly signiﬁ-
cant positive correlation between salivary CXCL13 and sever-
ity of sSS (r= 0.816, p< 0.001).
8. ROC curve for diagnosis of sSS from salivary CXCL13 levels
The cut off value of salivary CXCL13 level to diagnose sSS is
110 pg/ml, with sensitivity 80% and speciﬁcity 84% (Fig. 1).9. Discussion
The aim of this study was to measure the level of CXCL13 in
the plasma and unstimulated saliva of RA patients in order to
ﬁnd out its role in the disease activity of RA patients and its
relations to sSS.
Our study revealed a statistically highly signiﬁcant differ-
ence in the plasma and salivary levels of CXCL13 in RA pa-
tients compared to controls (p< 0.001). Our results were in
agreement with Rioja et al. [11] who found that there was a
statistically highly signiﬁcant difference in plasma CXCL13
levels between patients and normal controls (p< 0.001). Also
it was in agreement with Kramer et al. [13], whose study was
done on SS murine mice model, some had 1ry SS, others
had sSS, and normal controls. Serum and saliva were collected
from mice to detect CXCL13 levels, they found that there was
a statistically highly signiﬁcant difference between salivary
CXCL13 levels between the diseased mice and healthy mice
controls (p< 0.001). In our study the statistically highly sig-
niﬁcant difference between the salivary CXCL13 levels in pa-
tients without sSS (group2) and normal controls may
indicate that some patients in this group were in the preclinical
state of sSS, which needs further evaluation by ﬁnding out the
relation between the CXCL13 salivary levels and the number
of lymphocytes achieved by salivary gland tissue biopsies.
Rotondi et al. [12] found that B cells have been implicated
in the pathogenesis of SS. CXCL13 is one of the homeostatic
chemokines which are essential for lymphogenesis [19]. That
is why it is secreted in normal individuals under basal circum-
stances [10]. So, it was not surprising to report a detectable
amount of plasma and salivary CXCL13 in control subjects
of our study.
On comparing the plasma levels of CXCL13 between pa-
tients with sSS (group 1) and those without sSS (group2), there
was no statistically signiﬁcant difference (p> 0.05), this could
be explained by the high levels of circulating B cells which re-
lated to the pathogenesis of RA and SS disease as stated by
Maini et al. [20]. While on comparing the salivary levels of
CXCL13 between patients with sSS (group 1) and those with-
out sSS (group2), there was a statistically highly signiﬁcant in-
crease in patients with sSS (p< 0.001), this was conﬁrmed by
the work done by Barone and his colleagues [21], who did their
study on SS patients, some of them had SS secondary to RA,
taking salivary glands biopsies to detect the expression levels
of CXCL13 in salivary tissues in SS patients, and their results
strongly suggested the active participation of CXCL13 in the
development and maintenance of ectopic lymphoid structure
in SS. As well as, it may reﬂect the immunological scenario
in the salivary gland [22], but this result was not in agreement
with what is stated by Gabriela et al. [23] who collected stim-
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Figure 1 ROC curve for diagnosis of sSS from salivary CXCL13.
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ers with systemic autoimmune disease (SAD) without SS, and
32 healthy controls, to assess the saliva levels of CXCL13 in
patients and healthy controls, they found that no signiﬁcant
difference between salivary levels of CXCL13 in sSS and
SAD without SS, and this could be explained by the work done
by Kramer et al. [13], who stated that, stimulated saliva sam-
ples from their mice patients may lead to a diluted CXCL13
concentration.
Our results also revealed that, there was a statistically
highly signiﬁcant correlation between the disease duration of
RA and the plasma levels of CXCL13 (r= 0.406,
p< 0.001). The levels of salivary CXCL13 showed a statisti-
cally highly signiﬁcant correlation with the disease duration
of sSS(r= 0.536, p< 0.001).
In our work there was a statistically signiﬁcant correlation
between plasma levels of CXCL13 and CRP (r= 0.366,
p< 0.05) as well as ESR (r= 0.364, p< 0.05), this was in
accordance with the study done by Rioja et al. [11] who found
a statistically highly signiﬁcant correlation between CXCL13
plasma levels and ESR (r> 0.5, p< 0.001) as well as CRP
(r> 0.4, p< 0.001).
Regarding the correlation between plasma CXCL13 and
DAS 28, our results revealed a statistically highly signiﬁcant
correlation (r= 0.677, p< 0.001), Meanwhile Rioja et al.
[11] showed a borderline signiﬁcant correlation between DAS
28 and plasma CXCL13 levels, they also reported that plasma
levels of CXCL13 provide an accurate test for deﬁning the dis-
ease activity in RA patients, and this explained the above cor-
relations. On the other hand, salivary levels CXCL13 in our
study did not show any signiﬁcant correlation with DAS 28
(r= 0.104, p> 0.05).
Concerning the severity of sSS, our study showed a sta-
tistically highly signiﬁcant correlation between salivary levels
of CXCL13 and severity of sSS (r= 0.816, p< 0.001),
which was in accordance with what was stated by Barone
et al. [21] who found that, the acquisition of lymphoid fea-
tures by inﬂammatory foci in SS is critically associated with
the enlargement of the inﬂammatory foci and with theexpression of CXCL13. This also is in consistence with the
ﬁndings of Kramer et al. [13], who did their study to detect
salivary CXCL13 levels at early and late stage disease,
correlating its levels with the severity and progression of
SS; they found that salivary CXCL13 correlated with disease
severity of sSS.
Salivary CXCL13 also had a statistically highly signiﬁcant
role in the diagnosis of sSS with a cut off value 110 pg/ml,
where speciﬁcity was 84%, and sensitivity was 80%, this could
be explained by the involvement of CXCL13 pathogenetically
in Sjo¨gren’s syndrome development and progression, and its
levels in the serum and saliva may reﬂect the severity of the
SS disease in mice models as stated by Kramer et al. [13]. While
correlation of sSS severity with plasma CXCL13 there were no
statistical signiﬁcant correlations (r= 0.091, p> 0.05),
indicating that plasma CXCL13 might not be a severity
marker in sSS, and if its plasma level is elevated in sSS it
may be due to the activity of the original autoimmune disease
[13].
Markers like rheumatoid factor (RF) and anti–cyclic citrul-
linated peptide antibodies, which help to deﬁne the autoim-
mune status in RA [24] are not very responsive to changes in
levels of disease activity and are generally used only as prog-
nostic markers of disease severity. The erythrocyte sedimenta-
tion rate (ESR), shown to be the component with the highest
contribution in the DAS28 formula [25], is not very sensitive
to short-term changes in disease activity and can be inﬂuenced
by confounding factors, such as age, sex, ﬁbrinogen levels,
hypergammaglobulinemia, RF, and anemia [26]. Currently,
C-reactive protein (CRP), an acute phase response protein, is
the biomarker that is more widely used in clinical trials as a
marker of the efﬁcacy of potential disease-modifying com-
pounds. In addition, studies have suggested that serum levels
of (IL-6) correlate with levels of acute-phase proteins and
may also be useful as a tool for monitoring disease activity
in RA patients. However, due to the diurnal variability of
IL-6 [27], and the lack of disease selectivity of CRP, there is
a need for identifying and validating additional speciﬁc mark-
ers that can predict clinical outcomes.
126 N.M. Sherif et al.In conclusion, our results showed that plasma CXCL13 is a
novel biomarker of RA disease activity. The measurement of
salivary CXCL13 could be a useful new method to make the
deﬁnitive diagnosis of sSS, as it is correlated to severity of
sSS in humans since the appearance of sSS in RA patients is
independent of RA duration or activity [28]. It is considered
a non-invasive technique and it possesses a smaller amount
of proteins, meaning a minor risk of nonspeciﬁc interference
and hydrostatic interactions, and because it is directly collected
from the site of inﬂammation, it may reﬂect the immunological
scenario in the salivary gland.
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